Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Leukemia|March 24, 2026
Functional cooperation between the B-cell receptor and NOTCH1 in regulating metabolic reprogramming in chronic lymphocytic leukemiaAmelia Fascì, Francesco Edoardo Vallone, Nahal Nabelsi, et al.
Hematological Oncology|December 24, 2024
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic LeukemiaElena Bibikova, Sara Parsa, Muskan Floren, et al.
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
Blood|March 12, 2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphomaIan W Flinn, Brad S Kahl, John P Leonard, et al.
Leukemia & Lymphoma|July 21, 2012
Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1Kasyapa S Chitta, Aneel Paulus, Sikander Ailawadhi, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Blood|March 14, 2019
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemiaIan W Flinn, John G Gribben, Martin J S Dyer, et al.
Blood|March 12, 2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemiaJennifer R Brown, John C Byrd, Steven E Coutre, et al.
Blood|April 5, 2017
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLLPaul M Barr, Jennifer R Brown, Peter Hillmen, et al.
The Lancet. Oncology|December 17, 2013
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialSusan O'Brien, Richard R Furman, Steven E Coutre, et al.
Pageof 14